In Brief: Sarepta Filing Delay; Baxter Hemophilia Approval; Valeant To Increase Allergan Offer
This article was originally published in The Pink Sheet Daily
Sarepta says NDA submission for its muscular dystrophy treatment will be delayed until mid-2015 due to “new” and “updated” FDA requirements; agency approves Baxter’s porcine-sourced Obizur for acquired hemophilia A.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.